Open Access. Powered by Scholars. Published by Universities.®

Medicine and Health Sciences Commons

Open Access. Powered by Scholars. Published by Universities.®

Articles 1 - 14 of 14

Full-Text Articles in Medicine and Health Sciences

Design And Development Of A Mobile Health (Mhealth) Platform For Dementia Prevention In The Prevention Of Dementia By Mobile Phone Applications (Prodemos) Project, Melanie Hafdi, Esmé Eggink, Marieke P. Hoevenaar-Blom, M. Patrick Witvliet, Sandrine Andrieu, Linda Barnes, Carol Brayne, Rachael Brooks, Nicola Coley, Jean Georges, Abraham Van Der Groep, Harm Van Marwijk, Mark Van Der Meijden, Libin Song, Manshu Song, Youxin Wang, Wenzhi Wang, Wei Wang, Anders Wimo, Xiaoyan Ye, Eric P. Moll Van Charante, Edo Richard, Prodemos Consortium Dec 2021

Design And Development Of A Mobile Health (Mhealth) Platform For Dementia Prevention In The Prevention Of Dementia By Mobile Phone Applications (Prodemos) Project, Melanie Hafdi, Esmé Eggink, Marieke P. Hoevenaar-Blom, M. Patrick Witvliet, Sandrine Andrieu, Linda Barnes, Carol Brayne, Rachael Brooks, Nicola Coley, Jean Georges, Abraham Van Der Groep, Harm Van Marwijk, Mark Van Der Meijden, Libin Song, Manshu Song, Youxin Wang, Wenzhi Wang, Wei Wang, Anders Wimo, Xiaoyan Ye, Eric P. Moll Van Charante, Edo Richard, Prodemos Consortium

Research outputs 2014 to 2021

Background:

Mobile health (mHealth) has the potential to bring preventive healthcare within reach of populations with limited access to preventive services, by delivering personalized support at low cost. Although numerous mHealth interventions are available, very few have been developed following an evidence-based rationale or have been tested for efficacy. This article describes the systematic development of a coach-supported mHealth application to improve healthy lifestyles for the prevention of dementia and cardiovascular disease in the United Kingdom (UK) and China.

Methods:

Development of the Prevention of Dementia by Mobile Phone applications (PRODEMOS) platform built upon the experiences with the Healthy Aging …


Dementia Risk Reduction: Why Haven't The Pharmacological Risk Reduction Trials Worked? An In-Depth Exploration Of Seven Established Risk Factors, Ruth Peters, John Breitner, Sarah James, Gregory A. Jicha, Pierre-Francois Meyer, Marcus Richards, A. David Smith, Hussein N. Yassine, Erin L. Abner, Atticus H. Hainsworth, Patrick G. Kehoe, Nigel Beckett, Christopher Weber, Craig Anderson, Kaarin J. Anstey, Hiroko H. Dodge Dec 2021

Dementia Risk Reduction: Why Haven't The Pharmacological Risk Reduction Trials Worked? An In-Depth Exploration Of Seven Established Risk Factors, Ruth Peters, John Breitner, Sarah James, Gregory A. Jicha, Pierre-Francois Meyer, Marcus Richards, A. David Smith, Hussein N. Yassine, Erin L. Abner, Atticus H. Hainsworth, Patrick G. Kehoe, Nigel Beckett, Christopher Weber, Craig Anderson, Kaarin J. Anstey, Hiroko H. Dodge

Neurology Faculty Publications

Identifying the leading health and lifestyle factors for the risk of incident dementia and Alzheimer's disease has yet to translate to risk reduction. To understand why, we examined the discrepancies between observational and clinical trial evidence for seven modifiable risk factors: type 2 diabetes, dyslipidemia, hypertension, estrogens, inflammation, omega-3 fatty acids, and hyperhomocysteinemia. Sample heterogeneity and paucity of intervention details (dose, timing, formulation) were common themes. Epidemiological evidence is more mature for some interventions (eg, non-steroidal anti-inflammatory drugs [NSAIDs]) than others. Trial data are promising for anti-hypertensives and B vitamin supplementation. Taken together, these risk factors highlight a future need …


Higher Coffee Consumption Is Associated With Slower Cognitive Decline And Less Cerebral Aβ-Amyloid Accumulation Over 126 Months: Data From The Australian Imaging, Biomarkers, And Lifestyle Study, Samantha L. Gardener, Stephanie R. Rainey-Smith, Victor L. Villemagne, Jurgen Fripp, Vincent Doré, Pierrick Bourgeat, Kevin Taddei, Christopher Fowler, Colin L. Masters, Paul Maruff, Christopher C. Rowe, David Ames, Ralph N. Martins, Aibl Investigators Nov 2021

Higher Coffee Consumption Is Associated With Slower Cognitive Decline And Less Cerebral Aβ-Amyloid Accumulation Over 126 Months: Data From The Australian Imaging, Biomarkers, And Lifestyle Study, Samantha L. Gardener, Stephanie R. Rainey-Smith, Victor L. Villemagne, Jurgen Fripp, Vincent Doré, Pierrick Bourgeat, Kevin Taddei, Christopher Fowler, Colin L. Masters, Paul Maruff, Christopher C. Rowe, David Ames, Ralph N. Martins, Aibl Investigators

Research outputs 2014 to 2021

Background:

Worldwide, coffee is one of the most popular beverages consumed. Several studies have suggested a protective role of coffee, including reduced risk of Alzheimer’s disease (AD). However, there is limited longitudinal data from cohorts of older adults reporting associations of coffee intake with cognitive decline, in distinct domains, and investigating the neuropathological mechanisms underpinning any such associations.

Methods: The aim of the current study was to investigate the relationship between self-reported habitual coffee intake, and cognitive decline assessed using a comprehensive neuropsychological battery in 227 cognitively normal older adults from the Australian Imaging, Biomarkers, and Lifestyle (AIBL) study, over …


Effects Of The Tailored Activity Program (Tap) On Dementia-Related Symptoms, Health Events And Caregiver Wellbeing: A Randomized Controlled Trial, Laura N Gitlin, Katherine Marx, Catherine V. Piersol, Nancy A Hodgson, Jin Huang, David L Roth, Constantine Lyketsos Oct 2021

Effects Of The Tailored Activity Program (Tap) On Dementia-Related Symptoms, Health Events And Caregiver Wellbeing: A Randomized Controlled Trial, Laura N Gitlin, Katherine Marx, Catherine V. Piersol, Nancy A Hodgson, Jin Huang, David L Roth, Constantine Lyketsos

Department of Occupational Therapy Faculty Papers

BACKGROUND: People living with dementia (PLWD) and caregivers are adversely impacted by lack of meaningful activity leading to worse symptoms and impaired quality-of-life. There is a critical need to develop effective and well-tolerated treatments that mitigate clinical symptoms, engage PLWD and support caregiver wellbeing. We tested whether, compared to attention control, the Tailored Activity Program (TAP) reduced clinical symptoms and health-related events, and improved caregiver wellbeing, and if TAP activities were well-tolerated.

METHODS: We conducted a single-blind randomized controlled trial among 250 dyads recruited from Baltimore-Washington DC (2012-2016) with a dementia diagnosis and clinically significant agitation/aggression. Dyads were randomized to …


Committee On High-Quality Alzheimer’S Disease Studies (Chads) Consensus Report, Gregory A. Jicha, Erin L. Abner, Steven E. Arnold, Maria C. Carrillo, Hiroko H. Dodge, Steven D. Edland, Keith N. Fargo, Howard H. Feldman, Larry B. Goldstein, James A. Hendrix, Ruth Peters, Julie M. Robillard, Lon S. Schneider, Jodi R. Titiner, Christopher J. Weber Sep 2021

Committee On High-Quality Alzheimer’S Disease Studies (Chads) Consensus Report, Gregory A. Jicha, Erin L. Abner, Steven E. Arnold, Maria C. Carrillo, Hiroko H. Dodge, Steven D. Edland, Keith N. Fargo, Howard H. Feldman, Larry B. Goldstein, James A. Hendrix, Ruth Peters, Julie M. Robillard, Lon S. Schneider, Jodi R. Titiner, Christopher J. Weber

Sanders-Brown Center on Aging Faculty Publications

Background: Consensus guidance for the development and identification of high-quality Alzheimer's disease clinical trials is needed for protocol development and conduct of clinical trials.

Methods: An ad hoc consensus committee was convened in conjunction with the Alzheimer's Association to develop consensus recommendations.

Results: Consensus was readily reached for the need to provide scientific justification, registration of trials, institutional review board oversight, conflict of interest disclosure, funding source disclosure, defined trial population, recruitment resources, definition of the intervention, specification of trial duration, appropriate payment for participant engagement, risk-benefit disclosure as part of the consent process, and the requirement …


Early Indicators Of Cognitive Dysfunction: The Role Of Mild Behavioral Impairment, Hillary J. Rouse Jul 2021

Early Indicators Of Cognitive Dysfunction: The Role Of Mild Behavioral Impairment, Hillary J. Rouse

USF Tampa Graduate Theses and Dissertations

Older age is associated with an increased risk for cognitively impairing diseases such as dementia. Despite significant research to find ways to cure this disease, there has been little success. However, a critical need when an intervention is discovered is a need to find ways to identify people who are at the greatest risk of developing dementia earlier in the disease process so that interventions can be implemented at that time. This could potentially lessen their risk or delay when they are diagnosed. Using longitudinal data from the National Alzheimer’s Coordinating Center (NACC), the aims of this current dissertation were …


Dysregulation Of Systemic Immunity In Aging And Dementia, Jenny Lutshumba, Barbara S. Nikolajczyk, Adam D. Bachstetter Jun 2021

Dysregulation Of Systemic Immunity In Aging And Dementia, Jenny Lutshumba, Barbara S. Nikolajczyk, Adam D. Bachstetter

Pharmacology and Nutritional Sciences Faculty Publications

Neuroinflammation and the tissue-resident innate immune cells, the microglia, respond and contribute to neurodegenerative pathology. Although microglia have been the focus of work linking neuroinflammation and associated dementias like Alzheimer’s Disease, the inflammatory milieu of brain is a conglomerate of cross-talk amongst microglia, systemic immune cells and soluble mediators like cytokines. Age-related changes in the inflammatory profile at the levels of both the brain and periphery are largely orchestrated by immune system cells. Strong evidence indicates that both innate and adaptive immune cells, the latter including T cells and B cells, contribute to chronic neuroinflammation and thus dementia. Neurodegenerative hallmarks …


Q134r: Small Chemical Compound With Nfat Inhibitory Properties Improves Behavioral Performance And Synapse Function In Mouse Models Of Amyloid Pathology, Pradoldej Sompol, Jenna L. Gollihue, Susan D. Kraner, Irina A. Artiushin, Ryan A. Cloyd, Emad Chishti, Shon A. Koren, Grant K. Nation, Jose F. Abisambra, Orsolya Huzian, Lajos I. Nagy, Miklos Santha, Laszlo Hackler Jr., Laszlo G. Puskas, Christopher M. Norris Jun 2021

Q134r: Small Chemical Compound With Nfat Inhibitory Properties Improves Behavioral Performance And Synapse Function In Mouse Models Of Amyloid Pathology, Pradoldej Sompol, Jenna L. Gollihue, Susan D. Kraner, Irina A. Artiushin, Ryan A. Cloyd, Emad Chishti, Shon A. Koren, Grant K. Nation, Jose F. Abisambra, Orsolya Huzian, Lajos I. Nagy, Miklos Santha, Laszlo Hackler Jr., Laszlo G. Puskas, Christopher M. Norris

Sanders-Brown Center on Aging Faculty Publications

Inhibition of the protein phosphatase calcineurin (CN) ameliorates pathophysiologic and cognitive changes in aging rodents and mice with aging-related Alzheimer's disease (AD)-like pathology. However, concerns over adverse effects have slowed the transition of common CN-inhibiting drugs to the clinic for the treatment of AD and AD-related disorders. Targeting substrates of CN, like the nuclear factor of activated T cells (NFATs), has been suggested as an alternative, safer approach to CN inhibitors. However, small chemical inhibitors of NFATs have only rarely been described. Here, we investigate a newly developed neuroprotective hydroxyquinoline derivative (Q134R) that suppresses NFAT signaling, without inhibiting CN activity. …


Rule Out Screening For Undiagnosed Dementia And Alzheimer’S Disease Using An Ehr Based Machine Learning Solution, Branum Stephan, David A. Julovich, Dustin Bracy, Jeff Nguyen May 2021

Rule Out Screening For Undiagnosed Dementia And Alzheimer’S Disease Using An Ehr Based Machine Learning Solution, Branum Stephan, David A. Julovich, Dustin Bracy, Jeff Nguyen

SMU Data Science Review

Abstract. Current detection methods for Dementia and Alzheimer’s disease include cerebral spinal fluid (CSF) markers and/or the use of positron emission tomography (PET) imaging, both being high-cost, highly invasive testing methods. The need for low-cost, minimally invasive methods to prescreen individuals for cognitive impairment has been a challenge for many years. Today’s costs associated with an annual screen for all adults 65 and above using current methods (CSF, PET) reach well beyond trillions of dollars per year. Motivated by the limited accessibly and high costs, an alternative tool presented within this paper demonstrates an effective rule out screening for Dementia …


Sex, Diabetes Status And Cognition: Findings From The Study Of Longevity In Diabetes, Chris Moran, Paola Gilsanz, Michal S. Beeri, Rachel A. Whitmer, Mary E. Lacy Jan 2021

Sex, Diabetes Status And Cognition: Findings From The Study Of Longevity In Diabetes, Chris Moran, Paola Gilsanz, Michal S. Beeri, Rachel A. Whitmer, Mary E. Lacy

Epidemiology and Environmental Health Faculty Publications

INTRODUCTION: Women comprise two-thirds of people with dementia, making female sex a significant dementia risk factor. Both type 1 diabetes (T1D) and type 2 diabetes (T2D) are known dementia risk factors with an increasing global incidence. Understanding whether subtle sex differences persist in cognitive function prior to dementia in the context of diabetes may help elucidate the magnitude of sex effects on dementia risk.

RESEARCH DESIGN AND METHODS: We examined cross-sectional data from the Study of Longevity in Diabetes (SOLID), a prospective cohort study of members of Kaiser Permanente Northern California aged 60 years and older with T1D (n=758), T2D …


Intake Of Products Containing Anthocyanins, Flavanols, And Flavanones, And Cognitive Function: A Narrative Review, Samantha L. Gardener, Stephanie R. Rainey-Smith, Michael Weinborn, Catherine P. Bondonno, Ralph N. Martins Jan 2021

Intake Of Products Containing Anthocyanins, Flavanols, And Flavanones, And Cognitive Function: A Narrative Review, Samantha L. Gardener, Stephanie R. Rainey-Smith, Michael Weinborn, Catherine P. Bondonno, Ralph N. Martins

Research outputs 2014 to 2021

The purpose of this review is to examine human research studies published within the past 6 years which evaluate the role of anthocyanin, flavanol, and flavanone consumption in cognitive function, and to discuss potential mechanisms of action underlying any observed benefits. Evidence to date suggests the consumption of flavonoid-rich foods, such as berries and cocoa, may have the potential to limit, or even reverse, age-related declines in cognition. Over the last 6 years, the flavonoid subgroups of anthocyanins, flavanols, and flavanones have been shown to be beneficial in terms of conferring neuroprotection. The mechanisms by which flavonoids positively modulate cognitive …


Multiple Proteinopathies And Their Role In Cognitive Impairment And Neurodegenerative Diseases, Shama D. Karanth Jan 2021

Multiple Proteinopathies And Their Role In Cognitive Impairment And Neurodegenerative Diseases, Shama D. Karanth

Theses and Dissertations--Epidemiology and Biostatistics

Most age-related neurodegenerative disorders are associated with the aggregation of misfolded and aberrant proteins. Alzheimer’s disease (AD) is one of the most common neurodegenerative disorders and is highly prevalent in older adults. Neuropathologically, AD is characterized by the accumulation of amyloid-β (Aβ) plaques and neurofibrillary tangles (NFTs). Other misfolded proteins, including α-synuclein and transactive response DNA-binding protein 43 (TDP-43), are also commonly observed in aged brains. Aberrant α-synuclein has been associated with Parkinson's disease, Dementia with Lewy bodies, and multiple system atrophy, whereas TDP-43 has been associated with multiple neurological diseases, the most common of which was designated as limbic-predominant, …


Association Of Β-Amyloid Level, Clinical Progression And Longitudinal Cognitive Change In Normal Older Individuals, Laura M. Van Der Krall, Thanh Truong, Samantha C. Burnham, Vincent Doré, Rachel S. Mulligan, Svetlana Bozinovski, Fiona Lamb, Pierrick Bourgeat, Jurgen Fripp, Stephanie Schultz, Yen Y. Lim, Simon M. Laws, David Ames, Christopher Fowler, Stephanie R. Rainey-Smith, Ralph N. Martins, Olivier Salvado, Joanne Robertson, Paul Maruff, Colin L. Masters, Victor L. Villemagne, Christopher C. Rowe Jan 2021

Association Of Β-Amyloid Level, Clinical Progression And Longitudinal Cognitive Change In Normal Older Individuals, Laura M. Van Der Krall, Thanh Truong, Samantha C. Burnham, Vincent Doré, Rachel S. Mulligan, Svetlana Bozinovski, Fiona Lamb, Pierrick Bourgeat, Jurgen Fripp, Stephanie Schultz, Yen Y. Lim, Simon M. Laws, David Ames, Christopher Fowler, Stephanie R. Rainey-Smith, Ralph N. Martins, Olivier Salvado, Joanne Robertson, Paul Maruff, Colin L. Masters, Victor L. Villemagne, Christopher C. Rowe

Research outputs 2014 to 2021

Objective To determine the effect of β-amyloid (Aβ) level on progression risk to mild cognitive impairment (MCI) or dementia and longitudinal cognitive change in cognitively normal (CN) older individuals. Methods All CN from the Australian Imaging Biomarkers and Lifestyle study with Aβ PET and ≥ 3 years follow-up were included (n = 534; age 72 ± 6 years; 27% Aβ positive; follow-up 5.3 ± 1.7 years). Aβ level was divided using the standardized 0–100 Centiloid scale: < 15 CL negative, 15–25 CL uncertain, 26–50 CL moderate, 51–100 CL high, > 100 CL very high, noting > 25 CL approximates a positive scan. Cox proportional hazards analysis and linear mixed effect models were used to assess …


Prevention Of Dementia Using Mobile Phone Applications (Prodemos): Protocol For An International Randomised Controlled Trial, Esmé Eggink, Melanie Hafdi, Marieke P. Hoevenaar-Blom, Manshu Song, Sandrine Andrieu, Linda E. Barnes, Cindy Birck, Rachael L. Brooks, Nicola Coley, Elizabeth Ford, Jean Georges, Abraham Van Der Groep, Willem A. Van Gool, Ron Handels, Haifeng Hou, Dong Li, Hongmei Liu, Jihui Lyu, Harm Van Marwijk, Mark Van Der Meijden, Yixuan Niu, Shanu Sadhwani, Wenzhi Wang, Youxin Wang, Anders Wimo, Xiaoyan Ye, Yueyi Yu, Qiang Zeng, Wei Wang, Carol Brayne, Eric P. Moll Van Charante, Edo Richard Jan 2021

Prevention Of Dementia Using Mobile Phone Applications (Prodemos): Protocol For An International Randomised Controlled Trial, Esmé Eggink, Melanie Hafdi, Marieke P. Hoevenaar-Blom, Manshu Song, Sandrine Andrieu, Linda E. Barnes, Cindy Birck, Rachael L. Brooks, Nicola Coley, Elizabeth Ford, Jean Georges, Abraham Van Der Groep, Willem A. Van Gool, Ron Handels, Haifeng Hou, Dong Li, Hongmei Liu, Jihui Lyu, Harm Van Marwijk, Mark Van Der Meijden, Yixuan Niu, Shanu Sadhwani, Wenzhi Wang, Youxin Wang, Anders Wimo, Xiaoyan Ye, Yueyi Yu, Qiang Zeng, Wei Wang, Carol Brayne, Eric P. Moll Van Charante, Edo Richard

Research outputs 2014 to 2021

Introduction Profiles of high risk for future dementia are well understood and are likely to concern mostly those in low-income and middle-income countries and people at greater disadvantage in high-income countries. Approximately 30%-40% of dementia cases have been estimated to be attributed to modifiable risk factors, including hypertension, smoking and sedentary lifestyle. Tailored interventions targeting these risk factors can potentially prevent or delay the onset of dementia. Mobile health (mHealth) improves accessibility of such prevention strategies in hard-to-reach populations while at the same time tailoring such approaches. In the current study, we will investigate the effectiveness and implementation of a …